1. PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recurrent Glioblastoma. (18th October 2016) Authors: Shih, K.C.; Patel, M.R.; Butowski, N.; Falchook, G.S.; Kizilbash, S.H.; Bacha, J.A.; Brown, D.M.; Steino, A.; Schwartz, R.; Kanekal, S.; Lopez, L.M.; Burris, H.A. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022) Authors: Hong, D.; Shergill, A.; Bazhenova, L.; Cho, B.C.; Heist, R.; Moreno, V.; Falchook, G.S.; Nagasaka, M.; Cassier, P.; Besse, B.; Kim, D.W.; Yoon, S.; Le, X.; Zhao, T.; Atwal, S.; Park, E.; Lee, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S72 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗